§ 69511. General.
(a) This article specifies product-chemical combinations listed as Priority Products pursuant to section 69503.5.

(b) The following product-chemical combinations are listed as Priority Products:
   (1) Children’s foam-padded sleeping products containing tris(1,3-dichloro-2-propyl) phosphate (TDCPP) or tris(2-chloroethyl) phosphate (TCEP); and
   (2) Spray polyurethane foam systems containing unreacted methylene diphenyl diisocyanates.


§ 69511.2. Spray Polyurethane Foam Systems Containing Unreacted Methylene Diphenyl Diisocyanates.
(a) Product-chemical combination description: “Spray polyurethane foam systems containing unreacted methylene diphenyl diisocyanates” means spray polyurethane foam systems containing liquid chemical mixtures in two separate containers that are sold or distributed together. The two separate containers are commonly referred to as Side A and Side B. Side A contains unreacted methylene diphenyl diisocyanates. Side B contains a mixture of polyols and other ingredients which may include catalysts, blowing agents, flame retardants, and surfactants. The chemical mixtures in the sides react when mixed together to form polyurethane foam that is used for insulation, roofing, or sealing and filling voids and gaps. This product-chemical combination includes:
   (1) High-pressure spray polyurethane foam systems, and
   (2) Low-pressure spray polyurethane foam systems.

(b) Candidate Chemicals. For purposes of this chapter, the following Candidate Chemicals are identified as the basis for the product defined in subsection (a) being listed as a Priority Product:
   (1) 4,4’-methylenediphenyl diisocyanate, Chemical Abstract Service Reference Number: 101-68-8, and
   (2) Generic methylene diphenyl diisocyanate mixed isomers, Chemical Abstract Service Reference Number: 26447-40-5.

(c) Hazard traits associated with the Candidate Chemicals identified in subsection (b) include:
(1) Dermatotoxicity,  
(2) Immunotoxicity, and  
(3) Respiratory toxicity.

(d) Toxicological endpoints associated with exposure to Candidate Chemicals identified in subsection (b) include:

(1) Allergic contact dermatitis,  
(2) Allergic sensitization,  
(3) Asthma,  
(4) Dermal sensitization,  
(5) Extrinsic allergic alveolitis,  
(6) Hypersensitivity pneumonitis,  
(7) Interstitial and peribronchiolar fibrosis, and  
(8) Respiratory irritation.

(e) For purposes of this chapter, the Candidate Chemicals identified in subsection (b) are designated as Chemicals of Concern for the product defined in subsection (a).

(f) The Preliminary Alternatives Analysis Report for this Priority Product shall be submitted within 180 days after the effective date of this regulation.